GlassScriptPhysician profile
Robert Gertge
NPI 1356402374
$3,656.33
in general payments reported to CMS, 2019-2025
50 companies · $798 in 2025
The $798 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $644 · 2023: $806 · 2024: $911 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.71 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.45 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $199.37 | 2021-2024 | Xarelto, Spravato |
| Amgen INC. | $199.28 | 2021-2025 | Evenity, Prolia, Otezla |
| Neurocrine Biosciences, INC. | $182.69 | 2023-2025 | Ingrezza |
| Pfizer INC. | $137.06 | 2023-2025 | |
| Astellas Pharma US INC | $128.25 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.00 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $114.42 | 2021-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $89.83 | 2021-2025 | |
| Lundbeck LLC | $87.07 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $84.37 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dynavax Technologies Corporation | $79.86 | 2022-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $73.52 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $64.33 | 2021-2024 | Lokelma |
| Novartis Pharmaceuticals Corporation | $62.89 | 2021-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.81 | 2022-2025 | Gardasil 9, Capvaxive, Rotateq |
| Otsuka America Pharmaceutical, INC. | $60.48 | 2022-2025 | Rexulti |
| Kyowa Kirin, INC. | $57.77 | 2023-2024 | Nourianz, Crysvita |
| Lilly USA, LLC | $57.36 | 2021-2024 | Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $56.24 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $47.46 | 2023-2024 | Quviviq |
| Biogen, INC. | $45.86 | 2021-2024 | |
| Abbott Laboratories | $45.74 | 2024-2025 | Freestyle Libre 3 |
| Neurelis, INC. | $40.14 | 2021-2023 | Valtoco |
| Baxter Healthcare | $37.22 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $35.60 | 2021 | |
| Alkermes, INC. | $35.22 | 2022-2023 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $34.70 | 2022 | |
| Vanda Pharmaceuticals INC. | $34.26 | 2021 | |
| Cranial Technologies, INC | $33.94 | 2024 | Doc Band |
| Corium, LLC | $30.93 | 2023 | Adlarity |
| Phathom Pharmaceuticals, INC. | $30.75 | 2025 | Voquezna |
| Organon LLC | $28.16 | 2025 | Nexplanon |
| Neuronetics, INC. | $28.02 | 2025 | Neurostar Tms Therapy System |
| Indivior INC. | $25.07 | 2024 | Sublocade |
| Corcept Therapeutics | $24.10 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.20 | 2025 | Xifaxan |
| Ani Pharmaceuticals, INC. | $22.08 | 2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $20.55 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $20.07 | 2023 | Krystexxa |
| Lucid Diagnostics INC. | $20.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.48 | 2023 | |
| Redhill Biopharma INC. | $17.27 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.89 | 2022 | |
| Verona Pharma, INC. | $16.43 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $16.29 | 2021 | |
| Medtronic, INC. | $14.80 | 2022 | |
| Optinose US, INC. | $14.43 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.31 | 2022 | |
| Sumitomo Pharma America, INC. | $9.31 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gertge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.